Biotech | December 14, 2021
Moderna to set up mRNA vaccine manufacturing facility in Australia
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The company will manufacture a cancer immunotherapy product from 2022
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
The proposed week-long event will comprise specific themes - International engagements, market access and incubation support, funding support to startups etc. and will cover the different areas of the innovation lifecycle
It is a novel oral NLRP3 inflammasome inhibitor
The company is focused on the development of novel treatments for RNA viruses
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Subscribe To Our Newsletter & Stay Updated
